Parabilis Medicines

top of page

Mathai Mammen recaps the first clinical data Parabilis Medicines reported on its beta-catenin program earlier this month at EMSO and AACR-NCI-EORTC 2025. Plus, degraders for prostate cancer, and more.

He explains the company's "Helicon" peptide platform, and why he believes it is well suited to target previously undruggable problems like beta-catenin. Then he discusses clinical presentations on this program in multiple tumor types, and preclinical data on two degrader programs for prostate cancer.

Company News

Oct 31, 2025

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

Mathai Mammen recaps the first clinical data Parabilis Medicines reported on its beta-catenin program earlier this month at EMSO and AACR-NCI-EORTC 2025. Plus, degraders for prostate cancer, and more.

Follow BiotechTV

Sponsors

Sponsor Spotlight